BackCullinan Therapeutics Overview

Cullinan Therapeutics Long Term Debt

Cullinan Therapeutics's long-term debt is $1.7M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.66M
236.31% YoYΔ $1.17M vs prior year quarter

Peer average

Loading

Cullinan Therapeutics Long Term Debt History

Loading

Cullinan Therapeutics vs. peers: Long Term Debt Comparison

Loading

Cullinan Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cullinan Therapeutics (CGEM) FAQ

As of the most recent data (March 2026), CGEM shows a long-term debt of $1.7M. That compares with $490K in the prior-year period — up 236.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CGEM's long-term debt is now $1.7M (was $490K) — a 236.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cullinan Therapeutics is outperforming or lagging.

Tracking CGEM's long-term debt over time shows whether Cullinan Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.7M That compares with $490K in the prior-year period — up 236.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Cullinan Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.7M) with ownership activity and broader fundamentals.

Cullinan Therapeutics's long-term debt is $1.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.